AMLBreast cancerColon cancerGastric cancerLung cancerMyelomaOvarian cancerPancreatic cancer Breast cancerLiver cancerPan-cancer Breast cancerLiver cancerPan-cancer Breast cancer Custom Pan-cancer DNA Immunotherapy
Plot options
2. Select dataset:
METABRIC: long follow-up (median: 94 months), average characteristics (78% ER positive, 12% HER2 positive), treatment data available for this dataset only! TCGA: very short follow-up (median only 25 months), no grade. GSE40267: almost exclusively ER negative patients (92%). GSE19783: nodal status not available, 38% ER negative, high proportion of HER2 positive patients (18%).
By using the services, you agree to be bound by the Terms of Use.
Please note: the generated p value does not include correction for multiple hypothesis testing by default.
Please kindly cite our latest paper to support further development: Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer, Computational and Structural Biotechnology Journal, 2021;19:4101-4109, https://doi.org/10.1016/j.csbj.2021.07.014
KMplot.com Copyright © 2009-2024 | Contact | Sitemap